Biovail Corporation (USA) 

(Public, NYSE:BVF)   Watch this stock   
Find more results for BVF
Nov 18, 2009
Lazard Capital Healthcare Conference
Nov 12, 2009
Credit Suisse Healthcare Conference
Nov 5, 2009
Q3 2009 Earnings Release
Nov 5, 2009
Q3 2009 Earnings Conference Call - Webcast
Sep 21, 2009
UBS Global Life Sciences Conference
Sep 14, 2009
Morgan Stanley Global Healthcare Conference - Webcast
Sep 11, 2009
Thomas Weisel Partners Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 18.99% 26.40%
Operating margin 27.27% 15.09%
EBITD margin - 26.49%
Return on average assets 7.93% 11.74%
Return on average equity 12.72% 16.00%
Employees 1,368 -

Address

7150 Mississauga Road
Mississauga, ON L5N 8M5
Canada
+1-905-2863000 (Phone)
+1-905-6088118 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Biovail Corporation (USA) discussed on blogs

Ranking 700+ Mid-Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 15 hours ago
Stock Picks For Monday: Nanometrics, Melco Crown Entertainment ... - Antonio Costa - Daily Markets - 19 hours ago
Ranking 700+ Mid-Cap Stocks by Profit Margin - NASD100.com - Daily ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 20, 2009

Biovail Corporation (USA) discussions

  View all discussions »

Description

Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. The Company has various research and development, clinical research, manufacturing and commercial operations located in Barbados, Canada, the United States and Puerto Rico. Its main therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease. The primary markets for its products are the United States and Canada. On September 16, 2008, Biovail acquired Prestwick Pharmaceuticals, Inc.

Officers and directors

Douglas J.P. Squires Ph.D.
Chairman of the Board
Age: 60
Bio & Compensation - Reuters
William M. Wells
Chief Executive Officer, Director
Age: 48
Bio & Compensation - Reuters
Margaret Mulligan
Chief Financial Officer, Senior Vice President
Age: 50
Bio & Compensation - Reuters
Gilbert Godin
Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation - Reuters
Wendy A. Kelley
Senior Vice President, General Counsel, Corporate Secretary
Age: 45
Bio & Compensation - Reuters
Mark Durham
Senior Vice President - Human Resources and Shared Services
Age: 49
Bio & Compensation - Reuters
Gregory D. Gubitz
Senior Vice President - Corporate Development
Age: 51
Bio & Compensation - Reuters
Christine C. Mayer
Senior Vice-President - Business Development Services of Biovail Pharmaceuticals, Inc.
Age: 50
Bio & Compensation - Reuters
Michel Chouinard
Chief Operating Officer of Biovail Laboratories International SRL
Age: 52
Bio & Compensation - Reuters
H. Christian Fibiger
Senior Vice-President and Chief Scientific Officer of Biovail Laboratories International SRL (BLS)
Age: 65
Bio & Compensation - Reuters